Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|13|3|165-170

ISSN： 1574-8863

Source： Current Drug Safety, Vol.13, Iss.3, 2018-11, pp. : 165-170

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

By Park Keunchil   Goto Koichi  

Current Medical Research and Opinion, Vol. 22, Iss. 3, 2006-03 ,pp. : 561-573

Informa Healthcare

Access to resources Recommend Favorite

Estimated glomerular filtration rate and the risk–benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial

By  

JOURNAL OF INTERNAL MEDICINE, Vol. 283, Iss. 3, 2018-03 ,pp. : 314-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Established Acute Respiratory Distress Syndrome: Benefit of Corticosteroid Rescue Therapy

By  

Respiration, Vol. 65, Iss. 4, 1998-09 ,pp. : 258-264

Karger

Access to resources Recommend Favorite

Human papillomavirus vaccines: Understanding the benefit-risk

By Neels Pieter  

Annals of Medicine, Vol. 45, Iss. 3, 2013-05 ,pp. : 203-205

Informa Healthcare

Access to resources Recommend Favorite

Benefit–risk assessment of vitamin D supplementation

By Bischoff-Ferrari H.   Shao A.   Dawson-Hughes B.   Hathcock J.   Giovannucci E.   Willett W.  

Osteoporosis International, Vol. 21, Iss. 7, 2010-07 ,pp. : 1121-1132

Springer Publishing Company

Access to resources Recommend Favorite